Protara Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
Protara Therapeutics, Inc. (TARA) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 8.03 million shares for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2023-08-03
- 2023-06-30: Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6 month 8.03M shares.
- 2022-06-30: Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6 month 8.03M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6 month |
|---|---|
| 2023-06-30 | 8.03M shares 10-Q · filed 2023-08-03 |
| 2022-06-30 | 8.03M shares 10-Q · filed 2023-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |